Related Experiment Video
Updated: Jan 25, 2026
FISH for Pre-implantation Genetic Diagnosis
Published on: February 23, 2011
Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex
Catherine L Salussolia1, Katarzyna Klonowska2, David J Kwiatkowski2
1F.M. Kirby Neurobiology Center, Translational Neuroscience Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA;
Abstract:
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that affects multiple organ systems due to an inactivating variant in either TSC1 or TSC2, resulting in the hyperactivation of the mechanistic target of rapamycin (mTOR) pathway. Dysregulated mTOR signaling results in increased cell growth and proliferation. Clinically, TSC patients exhibit great phenotypic variability, but the neurologic and neuropsychiatric manifestations of the disease have the greatest morbidity and mortality. TSC-associated epilepsy occurs in nearly all patients and is often difficult to treat because it is refractory to multiple antiseizure medications. The advent of mTOR inhibitors offers great promise in the treatment of TSC-associated epilepsy and other neurodevelopmental manifestations of the disease; however, the optimal timing of therapeutic intervention is not yet fully understood.
Insights
Tuberous sclerosis complex (TSC) is a genetic disorder causing uncontrolled cell growth. mTOR inhibitors show promise for treating TSC-associated epilepsy, but optimal treatment timing requires further study.
Area of Science:
- Genetics
- Neuroscience
- Pharmacology
Background:
- Tuberous sclerosis complex (TSC) is an autosomal dominant disorder.
- It results from inactivating variants in TSC1 or TSC2 genes, leading to mechanistic target of rapamycin (mTOR) pathway hyperactivation.
- This dysregulated signaling promotes cell growth and proliferation, impacting multiple organ systems.
Purpose of the Study:
- To review the role of mTOR pathway hyperactivation in TSC.
- To discuss the therapeutic potential of mTOR inhibitors for TSC-associated epilepsy.
- To highlight the need for understanding optimal timing for mTOR inhibitor intervention.
Main Methods:
- Literature review of TSC pathogenesis and treatment.
- Analysis of current research on mTOR inhibitors in neurological disorders.
- Synthesis of clinical data regarding TSC-associated epilepsy and mTOR signaling.
Main Results:
- TSC is characterized by significant phenotypic variability, with neurological and neuropsychiatric issues causing the most severe outcomes.
- Nearly all TSC patients develop epilepsy, frequently resistant to standard antiseizure medications.
- mTOR inhibitors represent a promising therapeutic avenue for TSC-related epilepsy and neurodevelopmental problems.
Conclusions:
- Dysregulated mTOR signaling is a key driver of TSC pathogenesis, particularly in neurological manifestations.
- mTOR inhibitors offer a novel treatment strategy for difficult-to-treat TSC-associated epilepsy.
- Further research is essential to determine the optimal timing for initiating mTOR inhibitor therapy to maximize clinical benefit in TSC patients.
Related Concept Videos
01:27Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
01:22Nursing Diagnosis
The nursing diagnosis focuses on evidence-based...
02:16Genetics of Speciation
01:25What is Population Genetics?
00:49What is Genetic Engineering?
01:10Documentation of Nursing Diagnosis
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters...